Healthcare Equipment and Supplies
Company Overview of Asuragen, Inc.
Asuragen, Inc., a molecular diagnostics company, provides patient management solutions in oncology and genetic disorders. The company discovers, develops, and commercializes diagnostic products for use in clinical laboratories and bio/pharma partners’ diagnostic needs. It offers diagnostic products and services, which include AmplideX FMR1 PCR reagents for the detection of CGG repeats in the fragile X mental retardation (FMR1) gene; AmplideX FMR1 mPCR reagents for the detection of methylation status in the FMR1 gene; AmplideX FMR1 Controls, which are mixtures of genomic DNA containing multiple alleles; Analyte specific reagents; AmplideX PCR/CE FMR1 Reporter, an automated software system tha...
2150 Woodward Street
Austin, TX 78744
Founded in 2005
Key Executives for Asuragen, Inc.
Chief Executive Officer and President
Chief Financial Officer and Senior Vice President of Corporate Development
Senior Vice President of Operations
Senior Vice President of Commercial Operations
Compensation as of Fiscal Year 2016.
Asuragen, Inc. Key Developments
Asuragen, Inc. Announces the Launch of Custom Armored Rna Quant Zika Virus
Aug 9 16
Asuragen, Inc. announced the launch of custom Armored RNA Quant Zika Virus target for use in developing molecular assays. Asuragen’s proprietary Armored RNA Quant® technology is the gold standard for reliable, traceable standards for use with molecular assays developed for virus quantitation. The rapid emergence and spread of the Zika Virus globally has created an immediate need for high sensitivity and specificity assays for detection. Asuragen’s Armored RNA® technology has been widely used for qualitative and quantitative controls in the infectious diseases space since the emergence of molecular amplification-based assays for HIV and HCV in the 1990s. The development of a custom Armored RNA Quant® Zika target extends this unique capability to the assessment of this new, highly virulent and rapidly spreading global infectious disease. In collaboration with an expert in viral molecular diagnostics, Professor Jan Felix Drexler, Institute of Virology, University of Bonn Medical Center and the German Center for Infection Research (DZIF), Asuragen has developed a control that specifically targets critical, conserved regions of the Brazil Zika virus.
Asuragen Inc Launches AmplideX PCR/CE C9orf72 Kit for High-Resolution Genotyping of GC-Rich Repeat Expansions Relevant
Jul 6 16
Asuragen Inc. announced the launch of the AmplideX PCR/CE C9orf72 Kit. The PCR/capillary electrophoresis-based assay leverages the company’s proven, proprietary technology for analyzing high homology and GC-rich content. The company has established the commercial technology for the reliable amplification and analysis of CGG triplet repeats in the FMR1 gene, which is associated with Fragile X Syndrome, Autism, and FXTAS, a neurodegenerative disorder. The AmplideX PCR/CE C9orf72 Kit represents a further expansion of this technology into neurogenetics. The kit provides clinical and pharmaceutical researchers a method for high-resolution genotyping of hexanucleotide repeat expansions in C9orf72, a gene of emerging interest in frontotemporal dementia (FTD). Although most individuals have fewer than ten G4C2 repeats in C9orf72, this sequence can expand to hundreds or thousands of repeat units in patients with neurodegenerative diseases. Established C9orf72 PCR methods typically quantify only 30-45 repeats, and multiple PCR assays are often used to genotype unexpanded samples and flag large expansions. The company’s assay is a single-tube PCR that quantifies up to 145 repeats by capillary electrophoresis (CE), identifies both short and long expansions, and reports sequence variability near the repeat region using only 40 ng of genomic DNA. The kit streamlines existing workflows while delivering more insightful data and reducing the reliance on other cumbersome assays, such as Southern blotting.
Asuragen to Present Expansion of Next-Generation Sequencing Portfolio at American Association for Cancer Research Annual Meeting
Apr 18 16
Asuragen Inc. will showcase its newest Next-Generation Sequencing (NGS) technology capability in the Journal of Visualized Experiments and at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans on April 18, 2016. The data highlight the flexibility of Asuragen’s NGS-in-a-Box™ technology for DNA and RNA sequencing, and its applicability to the routine laboratory and non-small cell lung cancer (NSCLC). The QuantideX® NGS RNA Lung Cancer Panel, which will be commercially available in the third quarter of 2016, represents a significant improvement for clinical researchers with a greater than 50% improvement in turn-around time and a more than 30% reduction in hands-on time and associated costs. Data generated in collaboration with M.D. Anderson Cancer Center (Abstract #1389 “A Unified and Streamlined Targeted Sequencing System for the Quantification of DNA Mutations and RNA Expression Markers in Lung Cancer”) demonstrate strong analytical performance of the QuantideX® NGS System with challenging clinical samples. Results from the analyses of over 100 NSCLC FFPE patient samples reveal profiles of RNA translocations and DNA mutations consistent with lung adenocarcinoma and squamous cell carcinoma. These findings highlight how Asuragen’s NGS chemistries and software can be adapted to new content, as is also being demonstrated in a companion diagnostic project underway in oncology with a biotech partner and in collaboration with Illumina. This companion diagnostic partnership is one of Asuragen’s more than 20 active assay and product development collaborations with biotech and pharma partners in the clinical areas of inherited disease, oncology, infectious disease and neurodegenerative disease.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|